ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
0.5396
+0.0167 (3.19%)
At close: May 20, 2025, 4:00 PM
0.5362
-0.0034 (-0.63%)
Pre-market: May 21, 2025, 8:09 AM EDT
ZyVersa Therapeutics Employees
ZyVersa Therapeutics had 7 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,263,375
Market Cap
1.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ZVSA News
- 23 hours ago - ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases - GlobeNewsWire
- 8 days ago - ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewsWire
- 14 days ago - ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - GlobeNewsWire
- 22 days ago - ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease - GlobeNewsWire
- 27 days ago - ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status - GlobeNewsWire
- 6 weeks ago - ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewsWire
- 7 weeks ago - ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - GlobeNewsWire